Jaguar Health (JAGX) Set to Announce Quarterly Earnings on Tuesday

Jaguar Health (NASDAQ:JAGX) is scheduled to announce its earnings results before the market opens on Tuesday, November 14th. Investors interested in participating in the company’s conference call can do so using this link.

Jaguar Health (NASDAQ:JAGX) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter. Jaguar Health had a negative net margin of 402.00% and a negative return on equity of 1,146.88%. The company had revenue of $2.68 million for the quarter. On average, analysts expect Jaguar Health to post $-6 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Jaguar Health Price Performance

Shares of Jaguar Health stock opened at $0.29 on Friday. Jaguar Health has a 1 year low of $0.21 and a 1 year high of $11.99. The company has a current ratio of 0.97, a quick ratio of 0.69 and a debt-to-equity ratio of 2.89. The company has a 50 day simple moving average of $0.30 and a two-hundred day simple moving average of $0.49.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Jaguar Health in a research report on Monday, November 6th. They set a “sell” rating for the company.

Institutional Investors Weigh In On Jaguar Health

Hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp raised its stake in shares of Jaguar Health by 507.3% during the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock worth $120,000 after acquiring an additional 141,796 shares in the last quarter. Citigroup Inc. purchased a new position in shares of Jaguar Health during the first quarter worth approximately $34,000. Renaissance Technologies LLC purchased a new position in shares of Jaguar Health during the first quarter worth approximately $1,079,000. Goldman Sachs Group Inc. raised its stake in shares of Jaguar Health by 153.3% during the first quarter. Goldman Sachs Group Inc. now owns 54,770 shares of the biotechnology company’s stock worth $39,000 after acquiring an additional 33,148 shares in the last quarter. Finally, Virtu Financial LLC raised its stake in shares of Jaguar Health by 76.1% during the first quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 99,073 shares in the last quarter. 12.24% of the stock is currently owned by institutional investors.

About Jaguar Health

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.